Oppenheimer & Co. Inc. Sells 250 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Oppenheimer & Co. Inc. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,650 shares of the biotechnology company’s stock after selling 250 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Sarepta Therapeutics were worth $473,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Two Sigma Investments LP raised its stake in shares of Sarepta Therapeutics by 2,475.1% in the third quarter. Two Sigma Investments LP now owns 789,712 shares of the biotechnology company’s stock worth $87,295,000 after purchasing an additional 759,045 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 33.6% in the first quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after purchasing an additional 673,725 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Sarepta Therapeutics by 509.2% in the third quarter. Thrivent Financial for Lutherans now owns 699,483 shares of the biotechnology company’s stock worth $77,321,000 after purchasing an additional 584,654 shares during the last quarter. Pictet Asset Management SA raised its stake in shares of Sarepta Therapeutics by 459.7% in the third quarter. Pictet Asset Management SA now owns 667,044 shares of the biotechnology company’s stock worth $73,735,000 after purchasing an additional 547,857 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Sarepta Therapeutics by 124.8% in the third quarter. Renaissance Technologies LLC now owns 884,178 shares of the biotechnology company’s stock worth $97,737,000 after purchasing an additional 490,900 shares during the last quarter. 87.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. SVB Leerink restated an “outperform” rating and issued a $160.00 price target on shares of Sarepta Therapeutics in a research note on Friday, January 20th. Credit Suisse Group reduced their price objective on Sarepta Therapeutics from $144.00 to $139.00 and set a “neutral” rating for the company in a research report on Friday, March 17th. Citigroup started coverage on Sarepta Therapeutics in a research report on Tuesday, April 4th. They set a “buy” rating and a $179.00 price objective for the company. Mizuho reiterated a “buy” rating and set a $160.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, April 14th. Finally, The Goldman Sachs Group upped their price objective on Sarepta Therapeutics from $171.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $167.47.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $120.20 on Friday. The company has a current ratio of 4.63, a quick ratio of 4.26 and a debt-to-equity ratio of 1.73. Sarepta Therapeutics, Inc. has a 12-month low of $61.28 and a 12-month high of $159.84. The stock has a 50-day moving average price of $132.94 and a 200 day moving average price of $125.34. The stock has a market capitalization of $11.20 billion, a P/E ratio of -9.47 and a beta of 1.02.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last released its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.46) by $0.49. Sarepta Therapeutics had a negative return on equity of 128.64% and a negative net margin of 114.30%. The firm had revenue of $253.50 million during the quarter, compared to analysts’ expectations of $241.47 million. During the same quarter last year, the business posted ($1.20) earnings per share. The firm’s revenue was up 20.2% on a year-over-year basis. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post -10.18 EPS for the current fiscal year.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.